Item 8. Sero-monitoring of virus circulation and FMDV vaccination in the Caucasus

Provisional Timetable Tuesday 20th 8.30 AM Welcome and Introduction

Meeting procedures, Election of the Chairperson Update on EUFMD Commission and ongoing/planned actions under the EUFMD Strategic Plan 2005-8 and ECFAO agreement Summary of Research group Action Plan 2003-5 Keith Sumption Keith Sumption

Kris de Clercq

Co-ordinator or presenter

FMD risk and the review of priority antigens 9.30 FMD risk and the review of priority antigens for European vaccine banks [update on relevant cross-protection tests requested] David Paton

10.10 Break Question: Risk of FMDV type Asia-1 to Turkey 10.30 FMD Surveillance report – risk situation in Central Asia1 Manzoor Hussain, FAO Regional epidemiologist 11.00 FMD Surveillance report – risk situation in I.R of Iran Maghsoud Jamdar/Francis Geiger

11.30 Sero-monitoring for FMD infection in the Trans Caucasus Carsten Pötzsch

12.00 Discussion. Timetable for discussion of remaining surveillance items2 Identify reporting/working groups 12.30 Lunch 14.00 Tour of Greifswald and bus to FLI 16.30 Reporting/working groups3. At FLI 18.30 Dinner at FLI 22:00 Return to hotel If return earlier 21:00, then presentations may be made 21:00-22:00

Update from surveillance actions FMD surveillance in Turkey – progress report from surveillance actions in Erzurum province FMD surveillance in Turkey – progress report from sero-surveillance in Thrace region Tom Murray & Sinan Aktas Sinan Aktas

Wednesday 21st Question: what is the demand and who can supply the needs for external quality assurance of FMD labs? in our region Kris

8.30 am Inter-laboratory laboratory proficiency detection tests David

1 Paper on FMD in Tajikistan may be fitted here (Erika Carlsson, FAO animal health officer Tajikistan) 2 Monitoring situation in Turkey International Surveillance gaps and priorities International networking and issues in surveillance- OIE/FAO FMD network Other surveillance and control issues –Question of global cessation of Type C vaccination 3 To be decided by Chairman and will relate to need for specific reports for example R/WG on Asia-1 risk R/WG on international surveillance gaps R/WG on the needs of European NRLs /experts/labs within a global FMD network.